Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BerGenBio ASA
Denmark’s biotech Genmab has dropped the AXL targeted antibody-drug conjugate, enapotamab vedotin from early clinical development, and is focusing its resources on other therapeutic programs.
The Belgian drugmaker is getting hold of a device that delivers an inhaled formulation of the anxiety drug alprazolam which can rapidly terminate an epileptic seizure 30 seconds after it has begun.
In addition to our daily in-depth coverage of key events relating to the coronavirus, we’re bringing you a periodic round-up of other pandemic developments. This edition covers events at the national, European and global level.
The coronavirus pandemic could be a turning point for master protocol and platform trial designs, but clear guidance and coordination are still needed.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Antisense, Oligonucleotides
- Drug Discovery Tools